A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...
A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.
More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...
SURMOUNT-5’s results reflect those of multiple real-world studies, which have found that tirzepatide treatment results in ...
Eli Lilly's weight-loss drug Zepbound outperformed Novo Nordisk's Wegovy in a head-to-head trial, leading to a rise ...
Eli Lilly said its drug Zepbound led to greater weight reduction than rival Novo Nordisk's Wegovy in a head-to-head ...
Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...
As the Biden administration is proposing drugs like Ozempic and Wegovy be covered by Medicare and Medicaid, Black people need ...
A new study finds people who take weight-loss drugs also cut back on alcohol consumption. Researchers think the drugs could ...
Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and increased the price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback